Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IQQPH
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
CD70-glucocorticoid ADC
|
|||||
| Synonyms |
CD70-GC ADC; CD70 GC ADC
Click to Show/Hide
|
|||||
| Organization |
Ambrx, Inc.
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Ovarian cancer [ICD11:2C73]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
1.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
CD70 antigen (CD70)
|
Antigen Info | ||||
| Payload Name |
Fluticasone propionate
|
Payload Info | ||||
| Therapeutic Target |
Glucocorticoid receptor (NR3C1)
|
Target Info | ||||
| Linker Name |
Pyrophosphate linker
|
Linker Info | ||||
| Conjugate Type |
The drug linker was conjugated to the unnatural amino acid (UAA) para-azido phenylalanine (p-AF), replacing the alanine at position 1 of CH1 (HA114) of the antibody using copper-free 3 + 2 cycloaddition chemistry.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.